NCT05632744Completed
Evaluation of CG-100 Intraluminal Bypass Device
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
Evaluation of CG-100 Intraluminal Bypass device
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 7 (actual)
- First submitted
- 8 Nov 2022
- Start date
- 15 Mar 2023
- Primary completion date
- 15 Apr 2024
- Lead sponsor
- Colospan Ltd.
- Diseases
- Colorectal cancer
- NCT number
- NCT05632744
What you commit to
- Study type: Interventional
- Participants enrolled: 7
- From 15 Mar 2023 to the primary completion date, 15 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Willing to comply with protocol-specified follow-up evaluations
- 22-75 (inclusive) years of age at screening
- Diagnosed with colorectal cancer
- Has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
Age in the registry: 22 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Soroka Medical Center Coordinator of this site? Confirm its status | Rehovot | Israel | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.